Integra Lifesciences (IART)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 239,104 | 246,375 | 215,157 | 215,236 | 591,906 |
| Marketable Securities | 34,191 | 27,192 | 62,441 | 81,691 | 71,194 |
| Receivables | 252,446 | 272,370 | 248,298 | 271,155 | 241,092 |
| Inventories | 445,418 | 429,090 | 436,930 | 421,775 | 403,422 |
| Other current assets | 32,214 | 29,653 | 50,370 | 28,790 | 35,369 |
| TOTAL | $1,107,247 | $1,081,681 | $1,099,522 | $1,112,286 | $1,415,650 |
| Non-Current Assets | |||||
| PPE Net | 422,913 | 405,723 | 390,906 | 373,570 | 345,356 |
| Intangibles | 2,292,921 | 2,304,540 | 2,326,083 | 2,324,582 | 2,062,844 |
| Other Non-Current Assets | 229,670 | 245,480 | 249,292 | 264,057 | 254,374 |
| TOTAL | $2,945,504 | $2,955,743 | $2,966,281 | $2,962,209 | $2,662,574 |
| Total Assets | $4,052,751 | $4,037,424 | $4,065,803 | $4,074,495 | $4,078,224 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 573,899 | 573,170 | 572,442 | N/A | N/A |
| Accounts payable and accrued liabilities | 91,296 | 82,502 | 77,666 | 107,492 | 94,397 |
| Accrued Expenses | 189,797 | 207,525 | 208,363 | 172,087 | 164,478 |
| Other current liabilities | 10,539 | 10,483 | 9,990 | 9,905 | 7,841 |
| TOTAL | $918,452 | $922,126 | $912,563 | $328,316 | $302,394 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,230,641 | 1,196,017 | 1,205,092 | 1,229,365 | 1,265,636 |
| Other Non-Current Liabilities | 321,938 | 313,168 | 357,616 | 896,094 | 880,811 |
| TOTAL | $1,610,160 | $1,570,018 | $1,631,653 | $2,211,984 | $2,177,878 |
| Total Liabilities | $2,528,612 | $2,492,144 | $2,544,216 | $2,540,300 | $2,480,272 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 77,712 | 77,219 | 77,164 | 77,582 | 78,800 |
| Common Shares | 921 | 916 | 916 | 916 | 915 |
| Retained earnings | 914,622 | 939,915 | 920,481 | 931,176 | 943,578 |
| Other shareholders' equity | -24,485 | -27,982 | -24,664 | -18,479 | -11,068 |
| TOTAL | $1,524,139 | $1,545,280 | $1,521,587 | $1,534,195 | $1,597,952 |
| Total Liabilities And Equity | $4,052,751 | $4,037,424 | $4,065,803 | $4,074,495 | $4,078,224 |